Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.

Zeliadt SB, Potosky AL, Penson DF, Etzioni R
Int J Radiat Oncol Biol Phys. 2006 66 (2): 395-402

PMID: 16904843 · DOI:10.1016/j.ijrobp.2006.04.048

MeSH Terms (12)

Aged Aged, 80 and over Androgen Antagonists Chemotherapy, Adjuvant Humans Male Neoplasm Staging Proportional Hazards Models Prostatic Neoplasms SEER Program Socioeconomic Factors Survival Analysis

Connections (1)

This publication is referenced by other Labnodes entities: